Opdivo (nivolumab)

pCPA File Number: 22796

Negotiation Status:

Concluded with an LOI

Indication(s):

Renal Cell Carcinoma (RCC), advanced (not amenable to curative surgery or radiation therapy) or metastatic, first-line treatment of adult patients (in combination with nivolumab)

Sponsor/Manufacturer:

Bristol Myers Squibb Canada Inc.

CDA-AMC Project Number:

PC0312-000

pCPA Engagement Letter Issued:

2024-07-03

Negotiation Process Concluded:

2024-07-17